Hematologic disorders in liver failure: pathophysiology and therapeutic considerations
DOI:
https://doi.org/10.24265/horizmed.2024.v24n2.13Keywords:
Liver Cirrhosis , Thrombocytopenia , Leukopenia , Anemia , Bone Marrow , HypersplenismAbstract
Alterations in blood cell counts are the most prominent and recurrent clinical findings among patients suffering from both acute and chronic liver disease. These changes are an important marker of liver failure and often play a key role in the evaluation and management of these patients. Together with the prolongation of coagulation tests, thrombocytopenia is the most common disorder among these individuals. This condition, as well as leukopenia, is largely attributable to hypersplenism, a disorder in which the spleen retains and destroys blood cells, including platelets. However, when the platelet count drops below 10x103/µl, it is essential to consider other causes, such as autoimmune factors that may be contributing to the development of thrombocytopenia. Anemia, defined as a decrease in red blood cell count or hemoglobin levels, is another common characteristic of liver disease. Although in most cases macrocytic anemia occurs, in some situations it can be secondary to hemolytic events, as observed in Zieve’s syndrome. This wide range of manifestations of anemia among liver patients highlights the complex interaction between liver and blood components. Despite advances in understanding the underlying causes of these cytopenias, treatment options remain limited. Therapeutic options generally focus on the transfusion of blood products to compensate for deficiencies in cell counts or on the use of thrombopoietin (TPO) analogues to temporarily stimulate platelet production in the bone marrow. However, these treatments tend to address the symptoms rather than the root causes of hematologic disorders in liver disease. The persistence and worsening of these disorders may serve as early indicators of the progression of liver failure. The complicated relationship between liver and hematological homeostasis remains the subject of research. A deeper understanding of these mechanisms could potentially open the door toward more targeted and effective therapeutic approaches to address cytopenias in the context of liver disease.
Downloads
References
Nagao T, Hirokawa M. Diagnosis and treatment of macrocytic anemias in adults. J Gen Fam Med [Internet]. 2017;18(5):200–4.
Unnikrishnan V, Dutta TK, Badhe BA, Bobby Z, Panigrahi AK. Clinicoaetiologic profile of macrocytic anemias with special reference to megaloblastic anemia. Indian J Hematol Blood Transfus [Internet]. 2008;24(4):155–65.
Takahashi N, Kameoka J, Takahashi N, Tamai Y, Murai K, Honma R, et al. Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. Int J Hematol [Internet]. 2016;104(3):344–57.
Gupta PK, Saxena R, Karan AS, Choudhry VP. Red cell indices for distinguishing macrocytosis of aplastic anaemia and megaloblastic anaemia. Indian J Pathol Microbiol [Internet]. 2003;46(3):375–7.
Chandra H, Chandra S, Rawat A, Verma SK. Megaloblastic pancytopenia vis-à-vis non-megaloblastic pancytopenia: is mean platelet volume useful discriminating indicator. Int J Lab Hematol [Internet]. 2011;33(4):409–13.
Thompson WG. Red cell distribution width in alcohol abuse and iron deficiency anemia. JAMA [Internet]. 1992;267(8):1070–1.
Milić S, Mikolasević I, Radić M, Hauser G, Stimac D. Clinical utility of red cell distribution width in alcoholic and non-alcoholic liver cirrhosis. Coll Antropol [Internet]. 2011;35(2):335–8.
Maruyama S, Hirayama C, Yamamoto S, Koda M, Udagawa A, Kadowaki Y, et al. Red blood cell status in alcoholic and non-alcoholic liver disease. J Lab Clin Med [Internet]. 2001;138(5):332–7.
Veda P. Evaluation of macrocytosis in routine hemograms. Indian J Hematol Blood Transfus [Internet]. 2013;29(1):26–30. 10. Silber R, Amorosi E, Lhowe J, Kayden HJ. Spur-shaped erythrocytes in Laennec’s cirrhosis. N Engl J Med [Internet]. 1966;275(12):639–43.
Martinez-Maldonado M. Role of lipoproteins in the formation of spur cell anaemia. J Clin Pathol [Internet]. 1968;21(5):620–5.
Cooper RA, Diloy Puray M, Lando P, Greenverg MS. An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease. J Clin Invest [Internet]. 1972;51(12):3182–92.
Tariq T, Karabon P, Irfan FB, Sieloff EM, Patterson R, Desai AP. National trends and outcomes of nonautoimmune hemolytic anemia in alcoholic liver disease: Analysis of the Nationwide Inpatient Sample. J Clin Gastroenterol [Internet]. 2021;55(3):258–62.
Liu MX, Wen XY, Leung YK, Zheng YJ, Jin MS, Jin QL, et al.Hemolytic anemia in alcoholic liver disease: Zieve syndrome: A case report and literature review. Medicine (Baltimore) [Internet]. 2017;96(47):e8742.
Reyes JVM, Ahmad S, Majeed H, Kandoth E, Lieber JJ. Zieve syndrome: A clinical triad, or perchance a quartet? J Investig Med High Impact Case Rep [Internet]. 2022;10:1-3.
Gaur K, Puri V, Agarwal K, Suman S, Dhamija RK. Chronic liver disease presenting as immune hemolytic anemia: The challenges of diagnosis in the critically ill in a resource-limited health care setting. Cureus [Internet]. 2021;13(5):e14880.
Rajeev A, Padmakumar NN. Autoimmune Hemolytic Anemia in Chronic Liver Disease following COVID-19 episode. J Assoc Physicians India [Internet]. 2022;70(5):11–2.
Pop TL, Grama A, Stefanescu AC, Willheim C, Ferenci P. Acute liver failure with hemolytic anemia in children with Wilson’s disease: Genotype-phenotype correlations? World J Hepatol [Internet]. 2021;13(10):1428–38.
Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol [Internet]. 2009;15(37):4653–8.
Stein J, Connor S, Virgin G, Ong DEH, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol [Internet]. 2016;22(35):7908–25.
Gkamprela E, Deutsch M, Pectasides D. Iron deficiency anemia in chronic liver disease: etiopathogenesis, diagnosis and treatment. Ann Gastroenterol [Internet]. 2017;30(4):405–13.
Manrai M, Dawra S, Kapoor R, Srivastava S, Singh A. Anemia in cirrhosis: An underestimated entity. World J Clin Cases [Internet]. 2022;10(3):777–89.
Rostoker G, Lepeytre F, Merzoug M, Griuncelli M, Loridon C, Boulahia G, et al. Differential pharmacokinetics of liver tropism for iron sucrose, ferric carboxymaltose, and iron isomaltoside: A clue to their safety for dialysis patients. Pharmaceutics [Internet]. 2022;14(7):1408.
Shah AA, Donovan K, Seeley C, Dickson EA, Palmer AJR, Doree C, et al. Risk of infection associated with administration of intravenous iron: A systematic review and meta-analysis: A systematic review and meta-analysis. JAMA Netw Open [Internet]. 2021;4(11):e2133935.
Milic S, Mikolasevic I, Orlic L, Devcic E, Starcevic-Cizmarevic N, Stimac D, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit [Internet]. 2016;22:2144–51.
Datz C, Müller E, Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinol [Internet]. 2017;42(2):173–83.
Scheiner B, Semmler G, Maurer F, Schwabl P, Bucsics TA, Paternostro R, et al. Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver Int [Internet]. 2020;40(1):194204.
Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int [Internet]. 2017;37(6):778–93.
Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol [Internet]. 2008;15(5):473–80.
Saab S, Brown RS Jr. Management of thrombocytopenia in patients with chronic liver disease. Dig Dis Sci [Internet]. 2019;64(10):275768.
De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol [Internet]. 2022;76(4):959–74.
Pavel V, Scharf G, Mester P, Krauss LU, Gülow K, Mehrl A, et al. Partial splenic embolization as a rescue and emergency treatment for portal hypertension and gastroesophageal variceal hemorrhage. BMC Gastroenterol [Internet]. 2023;23(1):180.
Saeki M, Okubo H, Takasaki Y, Nakadera E, Fukuo Y, Fukada H, et al. The impact of partial splenic embolization on portal hypertensive gastropathy in cirrhotic patients with portal hypertension. J Clin Med [Internet]. 2023;12(7):2662.
Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol [Internet]. 2017;23(18):322839.
Dusheiko G. Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. Clin Liver Dis [Internet]. 2009;13(3):487–501.
Miller JB, Figueroa EJ, Haug RM, Shah NL. Thrombocytopenia in chronic liver disease and the role of thrombopoietin agonists. Gastroenterol Hepatol (NY) [Internet]. 2019;15(6):326–32.
Desai S, Subramanian A. Thrombocytopenia in chronic liver disease: Challenges and treatment strategies. Cureus [Internet]. 2021;13(7):e16342.
Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, et al. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, openlabel, phase II study. J Gastroenterol [Internet]. 2012;47(12):134251.
Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med [Internet]. 2012;367(8):716–24.
Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology [Internet]. 2018;155(3):70518.
Eguchi Y, Takahashi H, Mappa S, Santagostino E. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia. Hepatol Res [Internet]. 2022;52(4):371–80.
Yoshida M, Tateishi R, Hiroi S, Hongo Y, Fujiwara M, Kitanishi Y, et al. Effects of lusutrombopag on post-invasive procedural bleeding in thrombocytopenic patients with chronic liver disease. Adv Ther [Internet]. 2022;39(1):379–90.
Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology [Internet]. 2019;70(4):1336-48.
Tran TB, Downing L, Elmes JB, Arnall JR, Moore DC. Avatrombopag for the treatment of immune thrombocytopenia and periprocedural thrombocytopenia associated with chronic liver disease. J Pharm Pract [Internet]. 2022;37(1):184-9.
Bauman JW, Vincent CT, Peng B, Wire MB, Williams DD, Park JW. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol [Internet]. 2011;51(5):739–50.
Song AB, Al-Samkari H. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia. Expert Rev Clin Immunol [Internet]. 2022;18(8):783–91.
Ng YY, Lin CC, Wu SC, Hwang SJ, Ho CH, Yang WC, et al. Leukopenia and thrombocytopenia in hemodialysis patients with hepatitis B or C virus infection and non-hemodialysis patients with hepatitis cirrhosis. Clin Nephrol [Internet]. 2002;57(4):289–95.
Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug-induced thrombocytopenia: Mechanisms and laboratory diagnostics. Semin Thromb Hemost [Internet]. 2020;46(3):264–74.
Marks PW. Hematologic manifestations of liver disease. Semin Hematol [Internet]. 2013;50(3):216–21.
Qamar AA, Grace ND. Abnormal hematological indices in cirrhosis. Can J Gastroenterol [Internet]. 2009;23(6):441–5.
Lv Y, Yee Lau W, Wu H, Han X, Gong X, Liu N, et al. Causes of peripheral cytopenia in hepatitic cirrhosis and portal hypertensive splenomegaly. Exp Biol Med [Internet]. 2017;242(7):744–9.
Boyer TD, Habib S. Big spleens and hypersplenism: fix it or forget it? Liver Int [Internet]. 2015;35(5):1492–8.
Rivera AS, Valdelvira MG, Elia Martínez MA, Martí ÁF, Benito GM. Blue-green neutrophilic inclusion bodies with concurrent liver failure as a predictor of imminent death. Adv Lab Med [Internet]. 2022;3(3):295–302.
Berman L, Axelrod AR. The blood and bone marrow in patients with cirrhosis of the liver. J Lab Clin Med [Internet]. 1948;33(12):1628.
Varadarajan A, Lal D, Kapil R, Bihari C. Bone marrow dyspoiesis associated with severe refractory anaemia in liver cirrhosis. Frontline Gastroenterol [Internet]. 2021;12(1):39–43.
Kwak KA, Cho HJ, Yang JY, Park YS. Current perspectives regarding stem cell-based therapy for liver cirrhosis. Can J Gastroenterol Hepatol [Internet]. 2018;2018:4197857.
Kantarcıoğlu M, Demirci H, Avcu F, Karslıoğlu Y, Babayiğit MA, Karaman B, et al. Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis. Turk J Gastroenterol [Internet]. 2015;26(3):244–50.
Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S, et al. Randomized placebocontrolled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int [Internet]. 2013;33(10):1490–6.
Zekri AR, Salama H, Medhat E, Musa S, Abdel-Haleem H, Ahmed OS, et al. The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. Stem Cell Res Ther [Internet]. 2015;6(1):118.
Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology [Internet]. 2006;130(6):1807–21.
Magalhães RDS, Magalhães J, Sousa-Pinto B, Cúrdia Gonçalves T, Rosa B, Cotter J. Neutrophil-to-lymphocyte ratio: an accurate method for diagnosing infection in cirrhosis. Postgrad Med [Internet]. 2021;133(6):613–8.
Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes [Internet]. 2017;10(1):12.
Kwon JH, Jang JW, Kim YW, Lee SW, Nam SW, Jaegal D, et al. The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis. BMC Gastroenterol [Internet]. 2015;15(1):146.
Cervoni JP, Thévenot T, Weil D, Muel E, Barbot O, Sheppard F, et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol [Internet]. 2012;56(6):1299–304.
Itakura J, Kurosaki M, Setoyama H, Simakami T, Oza N, Korenaga M, et al. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol [Internet]. 2021;56(5):470–8.
Sapmaz FP, Büyükturan G, Sakin YS, Kalkan İH, Atasoy P. How effective are APRI, FIB-4, FIB-5 scores in predicting liver fibrosis in chronic hepatitis B patients? Medicine (Baltimore) [Internet]. 2022;101(36):e30488.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
